Malnutrition in patients with end-stage renal disease - Anorexia, cachexia and catabolism

Current Nutrition and Food Science

Volumn 3, Issue 1, 2007, Pages 37-46

  Axelsson, Jonas ^a   Carrero, Juan Jesús ^a   Lindholm, Bengt ^a   Heimbürger, Olof ^a   Stenvinkel, Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ACE inhibitors; Cannabinoids; Cardiovascular disease (CVD); IL 6 expression; Inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; APPETITE STIMULANT; ATORVASTATIN; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYPROHEPTADINE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRONABINOL; GHRELIN; GLITAZONE DERIVATIVE; HUMAN GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEGESTROL ACETATE; MELATONIN; NANDROLONE; OXANDROLONE; PLACEBO; PRAVASTATIN; RECOMBINANT SOMATOMEDIN C; SEVELAMER; SIMVASTATIN; STANOZOLOL; TESTOSTERONE; THALIDOMIDE;

ACIDOSIS; ANEMIA; ANOREXIA; CACHEXIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATABOLISM; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COMORBIDITY; DIET THERAPY; DIZZINESS; ENDOCRINE DISEASE; FOOD INTAKE; HUMAN; INFLAMMATION; KIDNEY FAILURE; MALNUTRITION; NONHUMAN; OUTCOME ASSESSMENT; PARANOIA; PRIORITY JOURNAL; PROTEIN DEPLETION; REVIEW; SIDE EFFECT; SKELETAL MUSCLE; SOMNOLENCE; WEIGHT GAIN;

EID: 33847027712     PISSN: 15734013     EISSN: None     Source Type: Journal    
DOI: 10.2174/1573401310703010037     Document Type: Review

References (122)

1. Heimburger O, Qureshi AR, Blaner WS, et al. Hand-grip muscle strength, lean body mass, and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. Am J Kidney Dis 2000; 36: 1213 -1225.
2. Young GA, Kopple JD, Lindholm B, et al. Nutritional assessment of continuous ambulatory peritoneal dialysis patients: an international study. Am J Kidney Dis 1991; 17: 462-471.
3. Qureshi AR, Alvestrand A, Danielsson A, et al. Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. Kidney Int 1998; 53: 773-782.
4. Mitch WE. Malnutrition: a frequent misdiagnosis for hemodialysis patients. J Clin Invest 2002; 110: 437-439.
5. Pupim LB, Ikizler TA. Assessment and monitoring of uremic malnutrition. J Ren Nutr 2004; 14: 6-19.
6. Enia G, Sicuso C, Alati G, et al. Subjective global assessement of nutrition in dialysis patients. Nephrol Dial Transplant 1993; 8: 1094-1098.
7. Jansen MAM, Korevaar JC, Dekker FW, et al. Renal function and nutritional status at the start of chronic dialysis treatment. J Am Soc Nephrol 2001; 12: 157-163.
8. Jager KJ, Merkus MP, Huisman RM, et al. Nutritional status over time in haemodialysis and peritoneal dialysis. J Am Soc Nephrol 2001; 12: 1272-1279.
9. Duenhas MR, Draibe SA, Avesani CM, et al. Influence of renal function on spontaneous dietary intake and on nutritional status of chronic renal insufficiency patients. Eur J Clin Nutr 2003; 57: 1473-1478.
10. Nelson EN, Hong CD, Pesce AL, et al. Anthropometric norms for the dialysis population. Am J Kidney Dis 1990; 16: 32-37.
11. Cianciaruso B, Brunori G, Kopple JD, et al. Cross-sectional comparison of malnutrition in continuous ambulatory dialysis and hemodialysis patients. Am J Kidney Dis 1995; 26: 475-483.
12. Ikizler TA, Greene JH, Wingard RL, et al. Spontaneous dietary intake during progression of chronic renal failure. Kidney Int 1995; 6: 1386-1391.
13. Stenvinkel P, Heimburger O, Lindholm B, et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000; 15: 953-960.
14. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019.
15. Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13: 1307-1320.
16. Bergström J, Lindholm B. Malnutrition, cardiac disease and mortality - An integrated point of view. Am J Kidney Dis 1998; 32: 834-841.
17. Stenvinkel P, Heimbürger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911.
18. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
19. Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658.
20. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998; 32 (Suppl 5): S112-S119.
21. Adey D, Kumar R, McCarthy JT, et al. Reduced synthesis of muscle proteins in chronic renal failure. Am J Physiol Endocrinol Metab 2000; 278: E219-225.
22. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int 2005; 67: 1216-1233.
23. Beddhu S, Kaysen GA, yan G, et al. Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis 2002; 40: 721-727.
24. Beddhu S, Pappas LM, Ramkumar N, et al. Malnutrition and atherosclerosis in dialysis patients. J Am Soc Nephrol 2004; 15: 733-742.
25. Aguilera A, Codoceo R, Selgas R, et al. Anorexigen (TNF-alpha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients. Their relationship with nutritional parameters. Nephrol Dial Transplant 1998; 13: 1476-1483.
26. Cheung W, Yu PX, Little BM, et al. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 2005; 115: 1659-1665.
27. Roubenoff R. Catabolism of aging: is it an inflammatory process? Curr Opin Clin Nutr Metab Care 2003; 6: 295-299.
28. Stenvinkel P, Heimburger O, Lindholm B: Wasting, but not malnutrition, predicts cardiovascular mortality in end-stage renal disease. Nephrol Dial Transplant 2004; 19: 2181-2183.
29. Stenvinkel P, Heimbürger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid atherosclerosis in dialysis patients: association to chlamydia pneumoniae seropositivity. Am J Kidney Dis 2002; 39: 274-282.
30. Stenvinkel P, Barany P, Heimburger O, et al. Mortality, malnutrition and atherosclerosis in end-stage renal disease: What is the role of interleukin-6? Kidney Int 2002; 61: S103-S108.
31. Strle K, Broussard SR, McCusker RH, el al. Proinflammatory cytokine impairment of insulin-like growth factor I-induced protein synthesis in skeletal muscle myoblasts requires ceramide. Endocrinology 2004; 145: 4592-4602.
32. Guttridge DC, Mayo MW, Madrid LV, et al. NF-kB-induced loss of MyoD messenger RNA: Possible role in muscle decay and cachexia. Science 2000; 289: 2363-2365.
33. Mitch WE, Du J, Bailey JL, et al. Mechanisms causing muscle proteolysis in uremia: the influence of insulin and cytokines. Miner Elect Metab 1999; 25: 216-219.
34. García-Martínez C, Llovera M, Agell N, et al. Ubiquitin gene expression in skeletal muscle is increased by tumor necrosis factor-a. Biochem Biophys Res Comm 1994; 201: 682-686.
35. Plata-Salamán CR: Cytokines and anorexia: A brief overview. Semin Oncology 1998; 25: 64-72.
36. Katschinski DM, Robins HI, Schad M, et al. Role of tumor necrosis factor alpha in hyperthermia-induced apoptosis of human leukemia cells. Cancer Res 1999; 59: 3404-3410.
37. Yeh SS, Schuster MW: Geriatric cachexia: the role of cytokines. Am J Clin Nutr 1999; 70: 183-197.
38. Grunfeld C, Zhao C, Fuller J, et al. Endotoxin and cytokines induce expression of leptin, the ob gene product in hamsters. A role for leptin in the anorexia of infection. J Clin Invest 1996; 97: 2152-2157.
39. Payette H, Roubenoff R, Jacques PF, et al. Insulin-like growth factor-1 and interleukin 6 predict sarcopenia in very old community-living men and women: The Framingham Heart Study. J Am Geriatr Soc 2003; 51: 1237-1243.
40. Bonafe M, Olivieri F, Cavallone L, et al. A gender-dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. Eur J Immunol 2001; 31: 2357-2361.
41. Goodman MN: Interleukin-6 induces skeletal muscle protein breakdown in rats. Proc Soc Exp Biol Med 1994; 205: 182-185.
42. Strassman G, Fong M, Kenney JS, et al. Evidence for the involvment of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992; 89: 1681-1684.
43. Tsujinaka T, Fujita J, Ebisuri C, et al. Interleukin-6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin-6 transgenic mice. J Clin Invest 1996; 97: 244-249.
44. Barbieri M, Ferruci L, Ragno E, et al. Chronic inflammation and the effect of IGF-1 on muscle strength and power in older persons. Am J Physiol Endocrinol Metab 2003; 284: E481-E487,
45. Kaizu Y, Ohkawa S, Odamaki M, et al. Association between inflammatory mediators and muscle mass in long-term hemodialysis patients. Am J Kidney Dis 2003; 42: 295-302.
46. Stenlof K, Wernstedt I, Fjallman T, et al. Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. J Clin Endocrinol Metab 2003; 88: 4379-4383.
47. Bammens B, Evenepoel P, Verbeke K, et al. Impairment of small intestinal protein assimilation in patients with end-stage renal disease: extending the malnutrition-inflammation-atherosclerosis concept. Am J Clin Nutr 2004; 80: 1536-1543.
48. Quinn LS, Anderson BG, Drivdahl RH, et al. Overexpression of interleukin-15 induces skeletal muscle hypertrophy in vitro: implications for treatment of muscle wasting disorders. Exp Cell Res 2002; 280: 55-63.
49. Carbo N, Lopez-Soriano J, Costelli P, et al. Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. Br J Cancer 2000; 83: 526-531.
50. Figueras M, Busquets S, Carbo N, et al. Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Lett 2004; 569: 201-206.
51. Harcourt LJ, Holmes AG, Gregorevic P, et al. Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice. Am J Pathol 2005; 166: 1131-1141.
52. Capelli JP, Kushner H, Canmiscioli TC, et al. Effect of intradialytic pareneteral nutrition on mortality rates in end-stage renal disease care. Am J Kidney Dis 1994; 23: 808-816.
53. Wolfson M. Use of nutritional supplements in dialysis patients. Semin Dial 1992; 5: 285-290.
54. Kalantar-Zadeh K, Block G, McAllister CJ, et al. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004; 80: 299-307.
55. Mehrotra R, Kopple JD: Causes of protein-energy malnutrition in chronic renal failure., in Nutritional management of renal disease (vol 167-182), edited by Kopple JD, Massry SG, 2nd ed, Philadelphia, Lippincott Williams & Wilkins, 2004.
56. Wynne Y, Giannitsopoulou K, Small CJ, et al. Subcutaneous Ghrelin Enhances Acute Food Intake in Malnourished Patients Who Receive Maintenance Peritoneal Dialysis: A Randomized, Placebo-Controlled Trial. J Am Soc; Nephrol 2005; (7): 2111-8.
57. Tchekmedyian N, Tait N, Moody M, et al. Appetite stimulation with megestrol acetate in cachectic cancer patients. Semin Oncol 1986; 13(Suppl 4): 37-43.
58. Lambert CP, Sullivan DH, Evans WJ. Effects of testosterone replacement and/or resistance training on interleukin-6, tumor necrosis factor alpha, and leptin in elderly men ingesting megestrol acetate: a randomized controlled trial. J Gerontol A Biol Sci Med Sci 2003; 58: 165-170.
59. Argiles JM, Meijsing SH, Pallares-Trujillo J, et al. Cancer cachexia: a therapeutic approach. Med Res Rev 2001; 21: 83-101.
60. Boccanfuso JA, Hutton M, McAllister B: The effects of megestrol acetate on nutritional parameters in a dialysis population. J Ren Nutr 2000; 10: 36-43.
61. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10: 89-97.
62. Golden AC, Daiello LA, Silverman MA, et al. University of Miami Division of clinical Pharmacology therapeutic rounds: Medications used to treat anorexia in the frail elderly. Am J Ther 2003; 10: 292-298.
63. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2020; 15: 567-573.
64. Nelson KA. Modern management of the cancer anorexia-cachexia syndrome. Curr Pain Headache Rep 2001; 5: 250-256.
65. Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs 1998; 55: 675-688.
66. Nascimento MM, Pecoits-Filho R, Lindholm B, et al. Inflammation, malnutrition and atherosclerosis in end-stage renal disease: a global perspective. Blood Purif 2002; 20: 454-458.
67. Iseki K, Tozawa M, Yoshi S, et al. Serum C-reactive (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transpl 1999; 14: 1956-1960.
68. Noh H, Lee SW, Kang SW, et al. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant 1998; 18: 387-394.
69. Wong JS, Port FK, Hulbert-Shearon TE, et al. Survival advantage in Asian American end-stage renal disease patients. Kidney Int 1999; 55: 2515-2523.
70. Morton MS, Arisaka O, Miyake N, et al. Phytoestrogen concentrations in serum from Japanese men and women over forty years of age. J Nutr 2002; 132: 168-171.
71. Evans MJ, Eckert A, Lai K, et al. Reciprocal antagonism between estrogen receptor and NF-kappaB activity in vivo. Circ Res 2001; 89: 823-830.
72. Ranich T, Bhathena SJ, Velasquez MT. Protective effects of dietary phytoestrogens in chronic renal disease. J Ren Nutr 2001; 11: 183-193.
73. King DE, Egan BM, Geesey ME. Relation of dietary fat and fiber to elevation of C-reactive protein. Am J Cardiol 2003; 92: 1335-1339.
74. Ciubotaru I, Lee YS, Wander RC. Dietary fish oil decreases C-reactive protein, interleukin-6 and tricylglycerol to HDL-cholesterol ratio in postmenopausal women on HRT. J Nutr Biochem 2003; 14: 513-521.
75. Kutner NG, Clow PW, Zhang R, et al. Association of fish intake and survival in a cohort of incident dialysis patients. Am J Kidney Dis 2002; 39: 1018-1024,
76. Gielen S, Adams V, Mobius-Winkler S, et al. Anti-inflammatory effects of excercise training in the skeletal muscle of patients with chronic heart failure, J Am Coll Cardiol 200; 342: 869-872.
77. Stack AG, Molony DA, Rives T, et al. Association of physical activity with mortality in the US dialysis population. Am J Kidney Dis 2005; 45: 690-701.
78. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 9: 1799-1804.
79. Imhof A, Koenig W: Alcohol inflammation and coronary heart disease. Addict Biol 2003; 8: 271-277.
80. Sabaté J. Nut consumption, vegetarian diets, ischemic heart disease risk, and all-cause mortality: evidence from epidemiologic studies. Am J Clin Nutr 1999; 79(Suppl): 500S-503S.
81. Cooney RV, Custer LJ, Okinaka L, et al. Effects of dietary sesame seeds on plasma tocopherol levels. Nutr Cancer 2001; 39: 66-71.
82. Jiang Q, Elson-Schwab I, Courtemanche C, et al. Gamma-tocopherol and its major metabolite, in contrast to alpha tocopherol, inhibit cycloxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci USA 2000; 97: 11494-11499.
83. Himmelfarb J, Stenvinkel P, Ikizler TA, et al. The elephant of uremia: oxidative stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538.
84. Stenvinkel P, Diczfalusy U, Lindholm B, et al. Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased mortality in patients on renal replacement therapy. Nephrol Dial Transplant 2004; 19: 972-976.
85. Hanninen O, Kaartinen K, Rauma A, et al. Antioxidants in vegan diet and rheumatic disorders. Toxicology 2000; 30: 45-53.
86. Tepel M, van der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107: 992-995.
87. Ivanovski O, Szumilak D, Nguyen-Khoa T, et al. The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int 2005; 67: 2288-2294.
88. Miyata T, Ishikawa S, Asahi K, et al. 2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after ballon injury of rat carotid artery: role of glycoxidation and lipooxidation reactions in vascular tissue damage. FEBS Lett 1999; 445: 202-206.
89. Suliman M, Heimburger O, Barany P, et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 2003; 14: 1614-1622,
90. Miyata T, Ishiguro N, Yasuda Y, et al. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation to inflammatory markers. Biochem Biophys Res Commun 1998; 244: 45-49.
91. Schwedler S, Schinzel R, Vaith P, et al. Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship? Kidney Int 2001; 59 (Suppl 78): S32-S36.
92. Uribarri J, Peppa M, Cai W, et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003; 14: 728-731.
93. Uribarri J, Peppa M, Cai W, et al. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis 2003; 42: 532-538.
94. Bakris GL, Bank AJ, Kass DA, et al. Advanced glycation end-product cross-link breakers: a novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 2004; 17: 23S-30S.
95. Forbes JM, Thallas V, Thomas MC, et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 2003; 17: 1762-1764.
96. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
97. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentrations of C-reactive protein. Circulation 1999; 100: 230-235.
98. Zhao SP, Zhang DQ. Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits. Clin Chim Acta 2003; 336: 103-108.
99. Hakamada-Taguchi I, Uehara Y, Kuribayashi K, et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 2003; 93: 948-956.
100. Nath N, Giri S, Prasad R, et al. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for multiple sclerosis therapy. J Immunol 2004; 172: 1273-1286.
101. Chang JW, Yang WS, Min WK, et al. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 2002; 39: 1213-1217.
102. Vernaglione L, Cristofano C, Muscogiuri P, et al. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis 2004; 43: 471-478.
103. Muscaritoli M, Costelli P, Bossola M, et al. Effects of simvastatin administration in an experimental model of cancer cachexia. Nutrition 2003; 19: 936-939.
104. Wurfel MM, Kunitake ST, Lichenstein H, et al. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994; 180: 1025-1035.
105. Rauchhaus M, Coats AJ, Anker SD: The endotoxin-lipoprotein hypothesis. Lancet 2000; 356: 930-933.
106. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients. Role of inflammation and malnutrition. JAMA 2004; 291: 451-459.
107. Peeters ACTM, Netea MG, Kullberg BJ, et al. The effect of renin-angiotensin system inhibitors on pro- and anti-inflamamtory cytokine production. Immunology 1998; 94: 376-379.
108. Brull DJ, Sanders J, Rumley A, et al. Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release. Heart 2002; 87: 252-255.
109. Stenvinkel P, Andersson A, Wang T, et al. Do ACE-inhibitors suppress tumor necrosis factor-a production in advanced chronic renal failure? J Int Med 1999; 246: 503-507.
110. Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003; 361: 1077-1083.
111. Moist LM, Port FK, Orzol SM, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11: 556-564.
112. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-636.
113. Saubermann LJ, Nakajima A, Wada, K, et al. Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis 2002; 8: 330-339.
114. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000; 49: 497-505.
115. Ferramosca E, Burke S, Chasan-Taber S, et al. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149: 820-825.
116. Qunibi WY. Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD). Kidney Int 2005; Suppl: s43-50.
117. Kopple JD, Brunori G, Leiserowitz M, et al. Growth hormone induces anabolism in malnourished maintenance haemodialysis patients. Nephrol Dial Transplant 2005; 20: 952-958.
118. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Ann Rev Med 2000; 51: 245-270,
119. Fouque D, Peng SC, Shamir E, et al. Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients. Kidney Int 2000; 57: 646-654.
120. Ericsson F, Divino JD, Lindgren B: Low grade inflammatory activity abolishes the anabolic effect of growth hormone (GH) on metabolism in hemodialysis patients. J Am Soc Nephrol 1999; 10: 162A.
121. Okamoto T. NSAID zaltoprofen improves the decrease in body weight in rodent sickness behavior models: proposed new applications of NSAIDs. Int J Mol Med 2002; 9: 369-372.
122. Davis TW, Zweifel BS, O'Neal JM, et al. Inhibition of COX-2 by Celecoxib Reverses Tumor Induced Wasting. Pharmacol Exp Ther 2004; 308: 929-34.